In today’s session Medtronic PLC (MDT) registered an unusually high (199) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious MDT increase. With 199 contracts traded and 664 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: MDT161216C00085000 closed last at: $3.4 or 4.2% down. About 1.09 million shares traded hands. Medtronic PLC (NYSE:MDT) has risen 15.19% since March 3, 2016 and is uptrending. It has outperformed by 6.85% the S&P500.
Medtronic PLC (NYSE:MDT) Ratings Coverage
Out of 17 analysts covering Medtronic (NYSE:MDT), 13 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 76% are positive. Medtronic has been the topic of 23 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Deutsche Bank maintained the stock with “Buy” rating in Thursday, June 2 report. On Tuesday, September 22 the stock rating was initiated by UBS with “Buy”. Goldman Sachs upgraded the stock to “Conviction Buy List” rating in Friday, November 13 report. Needham maintained Medtronic PLC (NYSE:MDT) rating on Tuesday, June 7. Needham has “Buy” rating and $93 price target. The stock of Medtronic PLC (NYSE:MDT) earned “Buy” rating by UBS on Friday, August 26. The stock has “Buy” rating given by Jefferies on Friday, August 26. The firm has “Outperform” rating given on Tuesday, September 29 by RBC Capital Markets. Citigroup initiated it with “Buy” rating and $102 target price in Tuesday, August 23 report. The rating was maintained by Morgan Stanley with “Overweight” on Wednesday, March 2. As per Monday, April 25, the company rating was initiated by SunTrust.
According to Zacks Investment Research, “Medtronic is the world’s leading medical technology company, pioneering device-based therapies that restore health, extend life and alleviate pain. Primary products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, among others. Medtronic operates its business in one reportable segment, that of manufacturing and selling device-based medical therapies. The company does business in more than 120 countries. The company’s product lines include cardiac rhythm management, neurological and spinal, vascular and cardiac surgery.”
Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.09, from 0.89 in 2016Q1. The ratio fall, as 60 funds sold all Medtronic PLC shares owned while 508 reduced positions. 93 funds bought stakes while 361 increased positions. They now own 1.03 billion shares or 1.89% more from 1.01 billion shares in 2016Q1.
Valicenti Advisory Services has invested 0.57% of its portfolio in Medtronic PLC (NYSE:MDT). Moreover, Lodestar Investment Counsel Limited Company Il has 0.08% invested in Medtronic PLC (NYSE:MDT) for 6,288 shares. Checchi Cap Advisers Ltd Company last reported 8,915 shares in the company. Macquarie Group last reported 0.05% of its portfolio in the stock. Investec Asset Mgmt North America Inc has 90,999 shares for 1.16% of their US portfolio. Alliancebernstein Lp accumulated 0.53% or 7.05M shares. Broderick Brian C holds 2,437 shares or 0.09% of its portfolio. Plante Moran Fincl Advsr Ltd Liability Company last reported 1,149 shares in the company. Hudock Capital Grp Limited Liability Co has invested 0.1% of its portfolio in Medtronic PLC (NYSE:MDT). Lba Wealth Ltd Co last reported 1,306 shares in the company. Horan Cap Mngmt last reported 0.05% of its portfolio in the stock. Nelson Roberts Investment Advsr Ltd Company has 0.01% invested in the company for 305 shares. M Hldgs Securities, a Oregon-based fund reported 6,752 shares. Union Bancshares Corporation reported 6,245 shares or 0.21% of all its holdings. Thompson Inv Mgmt holds 3,069 shares or 0.05% of its portfolio.
Medtronic Public Limited Company is a medical technology and services company. The company has a market cap of $118.98 billion. The Firm develops, makes and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. It has a 33.46 P/E ratio. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
MDT Company Profile
Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. The Company’s Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. The Company’s Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. The Company’s Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
More news for Medtronic PLC (NYSE:MDT) were recently published by: Finance.Yahoo.com, which released: “Medtronic Plc (MDT) Chairman & CEO Omar Ishrak Sold $5.3 million of Shares” on September 20, 2016. Reuters.com‘s article titled: “FDA approves Medtronic’s ‘artificial pancreas’ for diabetes” and published on September 28, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.